RESUMEN
The objective of this study was to evaluate a physiologically based pharmacokinetic (PBPK) approach for predicting the plasma concentration-time curves expected after intravenous administration of candidate drugs to rodents. The predictions were based on a small number of properties that were either calculated based on the structure of the candidate drug (octanol:water partition coefficient, ionization constant(s)) or obtained from the typical high-throughput screens implemented in the early drug discovery phases (fraction unbound in plasma and hepatic intrinsic clearance). The model was tested comparing the predicted and the observed pharmacokinetics of 45 molecules. This dataset included six known drugs and 39 drug candidates from different discovery programs, so that the performance of the model could be evaluated in a real discovery case scenario. The plasma concentration-time curves were predicted with good accuracy, the pharmacokinetic parameters being on average two- to three-fold of actual values. Multivariate analysis was used for identifying the candidate properties which were likely associated to biased predictions. The application of this approach was found useful for the prioritization of the in vivo pharmacokinetics screens and the design of the first-time-in-animal studies.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Modelos Biológicos , Farmacocinética , Acetamidas/sangre , Acetamidas/química , Acetamidas/farmacocinética , Algoritmos , Animales , Antiinfecciosos/sangre , Antiinfecciosos/química , Antiinfecciosos/farmacocinética , Antidepresivos/sangre , Antidepresivos/química , Antidepresivos/farmacocinética , Benzodiazepinas/sangre , Benzodiazepinas/química , Benzodiazepinas/farmacocinética , Cromanos/sangre , Cromanos/química , Cromanos/farmacocinética , Diltiazem/sangre , Diltiazem/química , Diltiazem/farmacocinética , Hipoglucemiantes/sangre , Hipoglucemiantes/química , Hipoglucemiantes/farmacocinética , Linezolid , Hígado/metabolismo , Ratones , Oxazolidinonas/sangre , Oxazolidinonas/química , Oxazolidinonas/farmacocinética , Análisis de Componente Principal , Ratas , Roedores , Tiazolidinedionas/sangre , Tiazolidinedionas/química , Tiazolidinedionas/farmacocinética , Distribución Tisular , Troglitazona , Zidovudina/sangre , Zidovudina/química , Zidovudina/farmacocinéticaRESUMEN
An approach to characterizing P-glycoprotein (Pgp) interaction potential for sparingly water-soluble compounds was developed using bidirectional transport kinetics in MDR1-MDCK cell monolayers. Paclitaxel, solubilized in a dilute polysorbate 80 (PS80) micellar solution, was used as a practical example. Although the passage of paclitaxel across the cell monolayer was initially governed by the thermodynamic activity of the micelle-solubilized drug solution, Pgp inhibition was sustained by the thermodynamic activity (i.e., critical micelle concentration) of the PS80 micellar solution bathing the apical (ap) membrane. The mechanistic understanding of the experimental strategies and treatment of data was supported by a biophysical model expressed in the form of transport events occurring at the ap and basolateral (bl) membranes in series whereas the vectorial directions of the transcellular kinetics were accommodated. The derived equations permitted the stepwise quantitative delineation of the Pgp efflux activity (inhibited and uninhibited by PS80) and the passive permeability coefficient of the ap membrane, the passive permeability at the bl membrane and, finally, the distinct coupling of these with efflux pump activity to identify the rate-determining steps and mechanisms. The Jmax/KM(∗) for paclitaxel was in the order of 10(-4) cm/s and the ap- and bl-membrane passive permeability coefficients were asymmetric, with bl-membrane permeability significantly greater than ap.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Permeabilidad de la Membrana Celular/fisiología , Lípidos/farmacocinética , Modelos Teóricos , Paclitaxel/metabolismo , Animales , Transporte Biológico/efectos de los fármacos , Transporte Biológico/fisiología , Células CACO-2 , Permeabilidad de la Membrana Celular/efectos de los fármacos , Perros , Relación Dosis-Respuesta a Droga , Humanos , Cinética , Lípidos/farmacología , Células de Riñón Canino Madin Darby , Paclitaxel/química , Paclitaxel/farmacologíaRESUMEN
The relationship of rotatable bond count (N(rot)) and polar surface area (PSA) with oral bioavailability in rats was examined for 434 Pharmacia compounds and compared with an earlier report from Veber et al. (J. Med. Chem. 2002, 45, 2615). N(rot) and PSA were calculated with QikProp or Cerius2. The resulting correlations depended on the calculation method and the therapeutic class within the data superset. These results underscore that such generalizations must be used with caution.
Asunto(s)
Disponibilidad Biológica , Preparaciones Farmacéuticas/química , Preparaciones Farmacéuticas/metabolismo , Administración Oral , Animales , Estructura Molecular , Preparaciones Farmacéuticas/administración & dosificación , Ratas , Relación Estructura-ActividadRESUMEN
P-glycoprotein (P-gp), a multidrug resistance (MDR) protein encoded by the MDR1 gene in humans, is responsible for the efflux of structurally diverse drugs. Previous studies in our laboratory have shown that excipients such as poly(ethylene)glycol (PEG)-300, Cremophor EL, and Tween 80 inhibit P-gp activity in Caco-2 cell monolayers. The objective of this study was to determine the effects of these excipients in an MDR1- transfected Madin Darby Canine Kidney (MDR1-MDCK) cell line and to compare the results with those obtained from Caco-2 cells. The results presented herein show that PEG-300 (20%, v/v) causes almost complete inhibition of P-gp activity in both Caco-2 and MDR1-MDCK cell monolayers, whereas Cremophor EL (0.1%, w/v) and Tween 80 (0.05%, w/v) only partially inhibit P-gp activity in Caco-2 cells. Cremophor EL (0.1%, w/v) and Tween 80 (0.05%, w/v) were inactive as P-gp inhibitors in MDR1-MDCK cell monolayers. This inability of Tween 80 and Cremphor EL to inhibit P-gp activity in MDR1-MDCK cells may be related to differences in the interactions of the surfactants with these different cell membranes. PEG-induced changes in P-gp activity are probably related to changes in the fluidity of the polar head group regions of cell membranes.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Excipientes/farmacología , Glicerol/análogos & derivados , Glicerol/farmacología , Polietilenglicoles/farmacología , Polisorbatos/farmacología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Animales , Transporte Biológico/efectos de los fármacos , Radioisótopos de Carbono , Línea Celular , Perros , Humanos , Manitol/farmacocinética , Fluidez de la Membrana/efectos de los fármacos , Paclitaxel/farmacocinética , TritioRESUMEN
Previous studies in our laboratories have shown that commonly used polyethoxylated pharmaceutical excipients inhibit P-glycoprotein activity in cell culture models of the intestinal mucosa. The results presented in this technical note show that the TECAN Genesis robotic workstation can be utilized to automate cellular transport studies for evaluating excipient effects on P-glycoprotein activity in vitro and for estimating the permeation of drug-like molecules across cell monolayers.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Polietilenglicoles/farmacocinética , Robótica/métodos , Tecnología Farmacéutica/métodos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Animales , Transporte Biológico/fisiología , Células CACO-2 , Línea Celular , Cromatografía Líquida de Alta Presión/métodos , Perros , Humanos , Robótica/instrumentación , Tecnología Farmacéutica/instrumentaciónRESUMEN
Solubility and cellular permeability are two of the most important biopharmaceutical properties impacting the successful development of drug substances. Given the importance of these properties, most pharmaceutical companies have invested in medium to high throughput technologies for early evaluation of these characteristics in the drug discovery funnel in order to select, prioritize or eliminate compounds with unfavorable solubility and/or permeability. However, these technologies require physical samples of the substances to be tested. In order to facilitate the early stages of drug discovery, such as defining compound collection composition, designing combinatorial libraries, and in hit expansion or lead optimization, models for predicting aqueous solubility and permeability in the absence of physical sample are increasingly being employed. In this overview, we will discuss solubility and permeability experimental and computational methods separately and then interrelate them in physiologically relevant models for predicting in vivo performance.
Asunto(s)
Proteínas Portadoras/metabolismo , Descubrimiento de Drogas/métodos , Preparaciones Farmacéuticas/química , Farmacocinética , Transportadoras de Casetes de Unión a ATP/metabolismo , Animales , Evaluación Preclínica de Medicamentos/métodos , Ensayos Analíticos de Alto Rendimiento/métodos , Humanos , Permeabilidad , SolubilidadRESUMEN
Significant recent work has focused on predicting drug absorption from structure. Several misperceptions regarding the nature of absorption seem to be common. Among these is that intestinal absorption, permeability, fraction absorbed, and, in some cases, even bioavailability, are equivalent properties and can be used interchangeably. A second common misperception is that absorption, permeability, etc. are discrete, fundamental properties of the molecule and can be predicted solely from some structural representation of the drug. In reality, drug absorption is a complex process dependent upon drug properties such as solubility and permeability, formulation factors, and physiological variables, including regional permeability differences, pH, lumenal and mucosal enzymology, and intestinal motility, among others. This article will explore the influence of these different variables on drug absorption and the implications with regards to attempting to develop predictive drug absorption algorithms.
Asunto(s)
Absorción Intestinal/fisiología , Preparaciones Farmacéuticas/metabolismo , Administración Oral , Animales , Relación Dosis-Respuesta a Droga , Predicción , Humanos , Permeabilidad , Relación Estructura-ActividadRESUMEN
PURPOSE: The purpose of this work was to evaluate an oral absorption prediction model, maximum absorbable dose (MAD), which predicts a theoretical dose of drug that could be absorbed across rat intestine based on consideration of intestinal permeability, solute solubility, intestinal volume, and residence time. METHODS: In the present study, Caco-2 cell permeability, as a surrogate for rat intestinal permeability, and aqueous solubility were measured for 27 oxazolidinones. The oxazolidinones are a novel class of potential antibacterial agents currently under investigation. These values were used to estimate MAD for each of the compounds. Finally, these predicted values were compared to previously measured bioavailability data in the rat in order to estimate oral absorption properties. RESULTS: A reasonably good correlation between predicted dose absorbed and bioavailability was observed for most of the compounds. In a few cases involving relatively insoluble compounds, absorption was underestimated. For these compounds while aqueous solubility was low. solubility in 5% polysorbate 80 was significantly higher, a solvent possibly more representative of the small intestinal lumen. CONCLUSIONS: These results suggest that MAD may be useful for prioritizing early discovery candidates with respect to oral absorption potential. In the case of compounds with poor aqueous solubility, additional factors may have to be considered such as solubility in the intestinal lumen.